Drug Trial Radar · NCT00046228
A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)
Last checked: Nov 20, 2026Latest source record: Jul 31, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,461
Actual
Start
Aug 2002
Primary completion
Jan 2008
Study completion Jan 2008
Sponsor
- Lead sponsor
- Centocor, Inc.Johnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- Collaborators
- Eli Lilly and Company
- First posted
- Sep 25, 2002
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether abciximab given in combination with reteplase, before patients have a coronary intervention (a standard treatment where a catheter is inserted into the heart artery to get blood flowing past the clot), is safe and effective in the treatment of heart attacks compared to only abciximab given during coronary intervention.
Conditions
- Myocardial Infarction
Interventions
abciximab placebo; reteplase placebo, abciximab, abciximabDrug
placebo bolus; 1-2 placebo bolus; 0.25 mg/kg bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
Abciximab; reteplase; abciximab placebo; abciximabDrug
0.25 mg/kg bolus; 1-2, 5 unit boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
abciximab; reteplase placebo; abciximab placebo; abciximabDrug
0.25 mg/kg bolus; 1-2 placebo boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
abciximab placebo; reteplase placebo, abciximab, abciximabDrug
placebo bolus; 1-2 placebo bolus; 0.25 mg/kg bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h
abciximab; reteplase placebo; abciximab placebo; abciximabDrug
0.25 mg/kg bolus; 1-2 placebo boluses; placebo bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h
Abciximab; reteplase; abciximab placebo; abciximabDrug
0.25 mg/kg bolus; 1-2, 5 unit boluses; placebo bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Composite of All-Cause Mortality or Complications of MI at 90 Days.Time frame: 90 days
Locations
227 sites in 19 countries. Site status is shown where the registry gives one.
Site not named
Phoenix, Arizona
Site not named
Covina, California
Site not named
Modesto, California
Site not named
Newark, Delaware
Site not named
Washington D.C., District of Columbia
Site not named
Clearwater, Florida
Site not named
Jacksonville, Florida
Site not named
Miami, Florida
Site not named
St. Petersburg, Florida
Site not named
Tallahassee, Florida
Site not named
Weston, Florida
Site not named
Harvey, Illinois
Site not named
Rock Island, Illinois
Site not named
Lexington, Kentucky
Site not named
Louisville, Kentucky
Site not named
New Orleans, Louisiana
Site not named
Lewiston, Maine
Site not named
Worcester, Massachusetts
Site not named
Ann Arbor, Michigan
Site not named
Pontiac, Michigan
Site not named
St Louis, Missouri
Site not named
Brooklyn, New York
Site not named
Flushing, New York
Site not named
Mineola, New York
Site not named
New York, New York
Site not named
Raleigh, North Carolina
Site not named
Winston-Salem, North Carolina
Site not named
Akron, Ohio
Site not named
Cleveland, Ohio
Site not named
Dayton, Ohio
Site not named
Westlake, Ohio
Site not named
Oklahoma City, Oklahoma
Site not named
Tulsa, Oklahoma
Site not named
Hershey, Pennsylvania
Site not named
Philadelphia, Pennsylvania
Site not named
Sayre, Pennsylvania
Site not named
Sellersville, Pennsylvania
Site not named
Upland, Pennsylvania
Site not named
Wormleysburg, Pennsylvania
Site not named
York, Pennsylvania
Showing 40 of 227 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.